Crinetics Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference

Rhea-AI Summary

SAN DIEGO, Nov. 22, 2022 – Crinetics Pharmaceuticals (Nasdaq: CRNX) will participate in the 5th Annual Evercore ISI HealthCONx Conference from November 29 to December 1, 2022. The company will host a fireside chat on November 30, 2022, at 1:00 PM (ET), moderated by Josh Schimmer, Research Analyst at Evercore ISI. The presentation will be accessible via the Evercore ISI platform and will be available for replay for 90 days. Interested parties can arrange virtual 1x1 meetings with Crinetics management through their bank or conference representative.

SAN DIEGO, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in a fireside chat and 1x1 investor meetings at the 5^th Annual Evercore ISI HealthCONx Conference being held virtually November 29 – December 1, 2022.

Details of the Crinetics fireside chat are as follows:

Date & Time:		November 30, 2022 at 1:00 PM (ET)
Moderator:		Josh Schimmer, Research Analyst, Evercore ISI
Webcast Link:		https://wsw.com/webcast/evercore29/crnx/2391810

 

The presentation may be accessed from the Evercore ISI platform or from the Events & Presentations page in the Investors section on the Company’s website. A replay of the presentation will be accessible for 90 days.

In addition, if you are interested in arranging a virtual 1×1 meeting with members of the Crinetics management team, please contact your bank/conference representative.

About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Paltusotine, an investigational, oral somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics has demonstrated pharmacologic proof-of-concept in Phase 1 clinical studies for CRN04777, an investigational, oral somatostatin receptor type 5 (SST5) agonist for congenital hyperinsulinism, and for CNR04894, an investigational, oral ACTH antagonist for the treatment of Cushing’s disease, congenital adrenal hyperplasia, and other diseases of excess ACTH. All of the company’s drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts.

Contact:
Investor Relations
ir@crinetics.com 
(858) 450-6464

Investors / Media:
Corey Davis
LifeSci Advisors
cdavis@lifesciadvisors.com 
(212)-915-2577

Aline Sherwood
Scienta Communications
asherwood@scientapr.com
(312) 238-8957

FAQ

When is Crinetics Pharmaceuticals participating in the Evercore ISI HealthCONx Conference?

Crinetics Pharmaceuticals will participate in the Evercore ISI HealthCONx Conference from November 29 to December 1, 2022.

What time is the Crinetics Pharmaceuticals fireside chat?

The Crinetics Pharmaceuticals fireside chat is scheduled for November 30, 2022, at 1:00 PM (ET).

Who is moderating the Crinetics Pharmaceuticals fireside chat?

The fireside chat will be moderated by Josh Schimmer, a Research Analyst at Evercore ISI.

Where can I access the Crinetics Pharmaceuticals presentation?

The presentation can be accessed on the Evercore ISI platform or the Events & Presentations page on Crinetics Pharmaceuticals' website.

Will there be a replay of the Crinetics Pharmaceuticals presentation?

Yes, a replay of the Crinetics Pharmaceuticals presentation will be available for 90 days.

How can I arrange a virtual meeting with Crinetics Pharmaceuticals management?

To arrange a virtual 1x1 meeting with Crinetics management, please contact your bank or conference representative.